Abstract
Autoimmune diseases are characterized by immune disorders that lead to abnormal activation of autoreactive immune cells, which in turn lead to tissue destruction and organ dysfunction. Compared with adults, autoimmune diseases in children are more severe, with increased disease activity and organ damage occurring earlier, and with higher mortality. In addition to the poor effect of traditional therapy in some children, children also have the needs for growth and development, and the use of traditional therapy will lead to severe immunosuppression and sequelae, affecting the quality of life of children. The emergence of Chimeric antigen receptors (CAR) cell therapy and biological agents has provided new treatment options for children with autoimmune diseases.